US 12,440,557 B2
Peptide immunogens and formulations thereof targeting membrane-bound IgE for treatment of IgE mediated allergic diseases
Chang Yi Wang, Cold Spring Harbor, NY (US); Feng Lin, Hauppauge, NY (US); and Jiun Bo Chen, Hauppauge (TW)
Assigned to United Biomedical, Inc., Hauppauge, NY (US)
Appl. No. 16/959,378
Filed by United Biomedical, Inc., Hauppauge, NY (US)
PCT Filed Dec. 31, 2017, PCT No. PCT/US2017/069174
§ 371(c)(1), (2) Date Jun. 30, 2020,
PCT Pub. No. WO2019/133024, PCT Pub. Date Jul. 4, 2019.
Prior Publication US 2023/0270848 A1, Aug. 31, 2023
Int. Cl. A61K 39/35 (2006.01); A61K 47/42 (2017.01); C07K 16/42 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/35 (2013.01) [A61K 47/42 (2013.01); C07K 16/4291 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55561 (2013.01)] 4 Claims
 
1. A peptide immunogen construct targeting an extracellular membrane-proximal domain of membrane-bound IgE (IgE EMPD), wherein the peptide immunogen construct consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 88-95, 98-124, and 130.